Search

Your search keyword '"Mistry, Haleigh"' showing total 19 results
Start Over Author "Mistry, Haleigh" Language english
19 results on '"Mistry, Haleigh"'

1. Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy

Author

Strati, Paolo, Jallouk, Andrew P., Sun, Ryan, Choi, Jaihee, Das, Kaberi, Cherng, Hua-Jay, Ahmed, Sairah, Lee, Hun J., Iyer, Swaminathan P., Nair, Ranjit, Nastoupil, Loretta J., Steiner, Raphael E., Huff, Chad D., Yu, Yao, Mistry, Haleigh, Pulsifer, Brittany, Noorani, Mansoor, Saini, Neeraj, Shpall, Elizabeth J., Kebriaei, Partow, Flowers, Christopher R., Westin, Jason R., Hildebrandt, Michelle A. T., and Neelapu, Sattva S.

Published
2022
Full Text
View/download PDF

2. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma

Author

Strati, Paolo, Nastoupil, Loretta J., Westin, Jason, Fayad, Luis E., Ahmed, Sairah, Fowler, Nathan H., Hagemeister, Fredrick B., Lee, Hun J., Iyer, Swaminathan P., Nair, Ranjit, Parmar, Simrit, Rodriguez, Maria A., Samaniego, Felipe, Steiner, Raphael E., Wang, Michael, Pinnix, Chelsea C., Adkins, Sherry, Claussen, Catherine M., Martinez, Charles S., Hawkins, Misha C., Johnson, Nicole A., Singh, Prachee, Mistry, Haleigh E., Horowitz, Sandra, George, Shirley, Feng, Lei, Kebriaei, Partow, Shpall, Elizabeth J., Neelapu, Sattva S., Tummala, Sudhakar, and Chi, T. Linda

Published
2020
Full Text
View/download PDF

8. Comorbidities Associated with Early Mortality after CD19 CAR-T Cell Therapy

Author

Tang, Kevin, Khwaja, Raamis, Feng, Lei, Strati, Paolo, Steiner, Raphael E., Nair, Ranjit, Flowers, Christopher R., Saini, Neeraj, Ramdial, Jeremy L., Srour, Samer A., Champlin, Richard E., Rondon, Gabriela, Torres, Janet, Kebriaei, Partow, Nastoupil, Loretta J., Mistry, Haleigh, Shpall, Elizabeth J., Nieto, Yago, Westin, Jason, Neelapu, Sattva S., and Ahmed, Sairah

Published
2022
Full Text
View/download PDF

10. 493 - Efficacy of Chimeric Antigen Receptor (CAR) T-Cell Therapy, Axicabtagene Ciloleucel (axi-cel), in Patients with Refractory Large B-Cell Lymphoma (LBCL)

Author

Ahmed, Sairah, Strati, Paolo, Fayad, Luis, Hagemeister, Frederick, Lee, Hun Ju, Iyer, Swaminathan P., Nair, Ranjit, Parmar, Simrit, Rodriguez, Alma, Samaniego, Felipe, Steiner, Raphael, Wang, Michael L., Pinnix, Chelsea, Flowers, Christopher, Horowitz, Sandra, Claussen, Catharine, Johnson, Nicole, Mistry, Haleigh, Adkins, Sherry, Shpall, Elizabeth J, Kebriaei, Partow, Nieto, Yago, Hawkins, Misha, Neelapu, Sattva S., Nastoupil, Loretta J., and Westin, Jason R.

Published
2021
Full Text
View/download PDF

11. Prognostic Value of Delta Lymphocyte Index (DLIx) in Patients with Large B-Cell Lymphoma (LBCL) Treated with Chimeric Antigen Receptor (CAR) T-Cell Therapy

Author

Strati, Paolo, Mistry, Haleigh, Pulsifer, Brittany, Fayad, Luis, Ahmed, Sairah, Lee, Hun Ju, Iyer, Swami P., Nair, Ranjit, Nastoupil, Loretta J., Parmar, Simrit, Rodriguez, Maria Alma, Samaniego, Felipe, Steiner, Raphael Eric, Wang, Michael, Pinnix, Chelsea C., Dabaja, Bouthaina S., Noorani, Mansoor, Claussen, Catherine M., Shpall, Elizabeth J., Kebriaei, Partow, Flowers, Chris R., Westin, Jason R., and Neelapu, Sattva S.

Published
2020
Full Text
View/download PDF

12. Response to pembrolizumab and lenalidomide in advanced refractory mycosis fungoides.

Author

Fountain, Eric, Mistry, Haleigh, Jain, Preetesh, Duvic, Madeleine, and Fowler, Nathan

Subjects
*MYCOSIS fungoides, *CUTANEOUS T-cell lymphoma, *SKIN diseases, *LYMPHOPROLIFERATIVE disorders, *T-cell lymphoma, *PROGRESSION-free survival
Abstract

The article presents a study that determines the effectiveness of immune-mediated therapy in the treatment of mycosis fungoides (MF) and cutaneous T-Cell lymphoma (CTCL). It observes several patients who were diagnosed with MF and CTCL and were given with the treatment intervention. It outlines the result which indicates that the patients have experienced dramatic, durable and ongoing response of the combined pembrolizumab and lenalidomide.

Published
2019
Full Text
View/download PDF

13. Toxicity Management: Development of a novel and immune-mediated adverse events algorithm.

Author

Mistry, Haleigh E., Forbes, Sheryl G., and Fowler, Nathan

Subjects
*HODGKIN'S disease treatment, *LYMPHOMA treatment, *ADRENOCORTICAL hormones, *ALGORITHMS, *CANCER patient medical care, *CANCER treatment, *COMBINATION drug therapy, *DRUG toxicity, *HEALTH care teams, *IMMUNOTHERAPY, *CASE studies, *EVIDENCE-based medicine, *PROFESSIONAL practice, *SPECIALTY hospitals
Abstract

BACKGROUND: Novel immunotherapy and biologic agents are being developed with the potential to improve outcomes and reduce long-term toxicities among individuals with hematologic malignancies. These emerging drugs affect neoplastic cells and the surrounding microenvironment, causing unique immune-mediated toxicities.
 OBJECTIVES: The aim was to develop an algorithm for clinical staff to manage unique toxicities associated with next-generation immunotherapies indicated in the hematologic population, using a system-focused approach.
 METHODS: Data were collected using specific toxicities based on the four major novel biologic classes. Immune-mediated adverse events were reported across studies. Based on published literature, institutional experience, and group consensus, a novel algorithm for managing immune-mediated toxicities was created.
 FINDINGS: The development of this treatment algorithm provides a more streamlined approach for managing common but unique toxicities and improves safety, compliance, patient outcome, and quality of life with novel immuno-oncologic agents. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

14. Integration of patient-reported outcomes into survivorship care.

Author

Gilmore, Katherine Ramsey, Chapman, Patricia Hansberry, Rollins, Johnny, Lee-Kim, Soo, Robinson, Justine, Mullen, Ellen, Mistry, Haleigh, Singh, Prachee, Coyne, Robin, Nelson, Ana, Osai, William, Stolar, Karen, Knippel, Susan, Fournier, Danielle M., Plair, Tamera, Peek, Angela, and Rodriguez, Maria Alma

Published
2022
Full Text
View/download PDF

15. Complete remission following lenalidomide and rituximab in a patient with heavily pretreated nodular lymphocyte predominant Hodgkin lymphoma.

Author

Cheah, Chan Yoon, Mistry, Haleigh E., Konoplev, Sergej, and Fowler, Nathan H.

Subjects
*HODGKIN'S disease treatment, *RITUXIMAB
Abstract

A letter to the editor is presented in response to the article about the complete remission of Hodkin lymhoma patient after the pretreatment of rituximab and lenaolidomide.

Published
2016
Full Text
View/download PDF

17. Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response.

Author

Jallouk AP, Gouni S, Westin J, Feng L, Mistry H, Steiner RE, James J, Noorani M, Horowitz S, Puebla-Osorio N, Fayad LE, Iyer SP, Hawkins M, Flowers CR, Ahmed S, Nastoupil LJ, Kebriaei P, Shpall EJ, Neelapu SS, Nieto Y, and Strati P

Subjects
Humans, Immunotherapy, Adoptive, Antigens, CD19, Lymphoma, Large B-Cell, Diffuse drug therapy, Lymphoma, Large B-Cell, Diffuse pathology, Biological Products therapeutic use
Published
2023
Full Text
View/download PDF

18. Biomarker Jeopardy.

Author

Kurtin SE, Henglefelt A, and Mistry H

Abstract

In the popular Biomarker Jeopardy session, Sandra E. Kurtin, PhD, ANP-C, AOCN®, Alyssa Henglefelt, PharmD, BCOP, and Haleigh Mistry, MS, PA-C, paired biomarkers with tumor types for which their expression is most commonly used to determine targeted therapy, identified key assays used to measure common biomarkers, and discussed guidelines for biomarker testing., Competing Interests: Dr. Kurtin has served as a consultant for AbbVie, Amgen, BMS, Celgene, GSK, and Incyte. Ms. Mistry reported financial relationships with ADC Therapeutics, Bayer, Astrazeneca, and Genentech/Roche. Dr. Henglefelt had no conflicts of interest to disclose., (© 2022 Harborside™.)

Published
2022
Full Text
View/download PDF

19. Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma.

Author

Strati P, Ahmed S, Furqan F, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Horowitz SB, Feng L, Sun R, Claussen CM, Hawkins MC, Johnson NA, Singh P, Mistry H, Johncy S, Adkins S, Kebriaei P, Shpall EJ, Green MR, Flowers CR, Westin J, and Neelapu SS

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Disease-Free Survival, Female, Humans, Male, Middle Aged, Retrospective Studies, Survival Rate, Adrenal Cortex Hormones administration & dosage, Dexamethasone administration & dosage, Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse mortality, Lymphoma, Large B-Cell, Diffuse therapy
Abstract

Corticosteroids are commonly used for the management of severe toxicities associated with chimeric antigen receptor (CAR) T-cell therapy. However, it remains unclear whether their dose, duration, and timing may affect clinical efficacy. Here, we determined the impact of corticosteroids on clinical outcomes in patients with relapsed or refractory large B-cell lymphoma treated with standard of care anti-CD19 CAR T-cell therapy. Among 100 patients evaluated, 60 (60%) received corticosteroids for management of CAR T-cell therapy-associated toxicities. The median cumulative dexamethasone-equivalent dose was 186 mg (range, 8-1803) and the median duration of corticosteroid treatment was 9 days (range, 1-30). Corticosteroid treatment was started between days 0 and 7 in 45 (75%) patients and beyond day 7 in 15 (25%). After a median follow-up of 10 months (95% confidence interval, 8-12 months), use of higher cumulative dose of corticosteroids was associated with significantly shorter progression-free survival. More importantly, higher cumulative dose of corticosteroids, and prolonged and early use after CAR T-cell infusion were associated with significantly shorter overall survival. These results suggest that corticosteroids should be used at the lowest dose and for the shortest duration and their initiation should be delayed whenever clinically feasible while managing CAR T-cell therapy-associated toxicities., (© 2021 by The American Society of Hematology.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results